SELLAS Life Sciences (SLS) EPS (Weighted Average and Diluted) (2011 - 2026)
SELLAS Life Sciences (SLS) reported EPS (Weighted Average and Diluted) of -$0.05 for Q1 2026, up 28.57% year-over-year from -$0.04 in Q1 2025, and little changed quarter-over-quarter from -$0.05 in Q4 2025.
SELLAS Life Sciences (SLS) EPS (Weighted Average and Diluted) (2011 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 13 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.05 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.05, up 28.57% year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.23 (up 39.47% YoY), and the FY2025 annual result was -$0.25, up 50.0% from the prior year.
- EPS (Weighted Average and Diluted) steadied at -$0.05 in Q1 2026 per SLS's latest filing, from -$0.05 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at -$0.05 in Q4 2025 and troughed at -$1.05 in Q1 2022.
- A 5-year average of -$0.26 and a median of -$0.21 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2022 and 2024: EPS (Weighted Average and Diluted) slumped 556.25% in 2022, then soared 69.7% in 2024.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.43 in 2022, then soared by 41.86% to -$0.25 in 2023, then surged by 68.0% to -$0.08 in 2024, then jumped by 37.5% to -$0.05 in 2025, then retreated by 0.0% to -$0.05 in 2026.
- Business Quant data shows SLS's EPS (Weighted Average and Diluted) at -$0.05 in Q1 2026, -$0.05 in Q4 2025, and -$0.06 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - | -0.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.05 |
| Dec 31, 2025 | -0.05 |
| Sep 30, 2025 | -0.06 |
| Jun 30, 2025 | -0.07 |
| Mar 31, 2025 | -0.07 |
| Dec 31, 2024 | -0.08 |
| Sep 30, 2024 | -0.10 |
| Jun 30, 2024 | -0.13 |
| Mar 31, 2024 | -0.21 |
| Dec 31, 2023 | -0.25 |
| Sep 30, 2023 | -0.33 |
| Jun 30, 2023 | -0.31 |
| Mar 31, 2023 | -0.47 |
| Dec 31, 2022 | -0.43 |
| Sep 30, 2022 | -0.34 |
| Jun 30, 2022 | -0.41 |
| Mar 31, 2022 | -1.05 |
| Dec 31, 2021 | -0.42 |
| Sep 30, 2021 | -0.45 |
| Jun 30, 2021 | -0.30 |